Bone disease after renal transplantation

Nephrology Dialysis Transplantation

Volumn 23, Issue 2, 2008, Pages 450-458

  Kunzendorf, Ulrich ^a   Krämer, Bernhard K ^b   Arns, Wolfgang ^c   Braun, Johann ^d   Grossmann, Jan ^d   Pietruck, Frank ^e   Schmidt Gayk, Heinrich ^f   Schwarz, Anke ^g   Ziegler, Ekkehard ^a   Sperschneider, Heide ^d   Wüthrich, Rudolf P ^h   Nonnast Daniel, Barbara ⁱ   Schindler, Ralf ^j   Renders, Lutz ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c Department of Internal Medicine

^d Kuratorium für Dialyse und Transplantation ^*  (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f Laboratory Dr Limbach and Colleagues   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY OF ZURICH   (Switzerland)

ⁱ UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

Hyperparathyroidism; Kidney transplantation; Renal osteopathy

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CINACALCET; COLECALCIFEROL; CYCLOSPORIN; DIPYRIDAMOLE; IBANDRONIC ACID; IMMUNOSUPPRESSIVE AGENT; PAMIDRONIC ACID; PHOSPHATE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; STEROID; TACROLIMUS; VITAMIN D;

BONE DISEASE; BONE NECROSIS; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG HALF LIFE; FRACTURE; HUMAN; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPERTHYROIDISM; HYPOPHOSPHATEMIA; KIDNEY TRANSPLANTATION; MONOTHERAPY; NONHUMAN; OSTEITIS FIBROSA; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROIDECTOMY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE;

BONE DISEASES; HUMANS; HYPOPHOSPHATEMIA; KIDNEY TRANSPLANTATION;

EID: 44449091981     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm816     Document Type: Review

References (78)

1. Rojas E, Carlini RG, Clesca P et al. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int 2003; 63: 1915-1923
2. O'Shaughnessy EA, Dahl DC, Smith CL et al. Risk factors for fractures in kidney transplantation. Transplantation 2002; 74: 362-366
3. Patel S, Kwan JT, McCloskey E et al. Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res 2001; 16: 1863-1870
4. Seeman E. Osteoporosis: trials and tribulations. Am J Med 1997; 103: 74S-87S
5. Ball AM, Gillen DL, Sherrard D et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002; 288: 3014-3018
6. Mulder JE, Kolatkar NS, LeBoff MS. Drug insight: existing and emerging therapies for osteoporosis. Nat Clin Pract Endocrinol Metab 2006; 2: 670-680
7. Grotz WH, Mundinger FA, Gugel B et al. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation 1994; 58: 912-915
8. Durieux S, Mercadal L, Orcel P et al. Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation 2002; 74: 496-500
9. Coco M, Glicklich D, Faugere MC et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003; 14: 2669-2676
10. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266
11. Evenepoel P, Claes K, Kuypers D et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 2004; 19: 1281-1287
12. Dumoulin G, Hory B, Nguyen NU et al. No trend toward a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients. Am J Kidney Dis 1997; 29: 746-753
13. Heaf J, Tvedegaard E, Kanstrup IL et al. Bone loss after renal transplantation: role of hyperparathyroidism, acidosis, cyclosporine and systemic disease. Clin Transplant 2000; 14: 457-463
14. Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997; 51: 328-336
15. Jilka RL, Weinstein RS, Bellido T et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104: 439-446
16. Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-3602
17. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999; 140: 3552-3561
18. Murray TM, Rao LG, Divieti P et al. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocr Rev 2005; 26: 78-113
19. Gwinner W, Suppa S, Mengel M et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005; 5: 1934-1941
20. Ambuhl PM, Meier D, Wolf B et al. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 1999; 34: 875-883
21. Green J, Debby H, Lederer E et al. Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. Kidney Int 2001; 60: 1182-1196
22. Felsenfeld AJ, Gutman RA, Drezner M et al. Hypophosphatemia in long-term renal transplant recipients: effects on bone histology and 1,25-dihydroxycholecalciferol. Miner Electrolyte Metab 1986; 12: 333-341
23. Murer H, Hernando N, Forster I et al. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 2000; 80: 1373-1409
24. Riancho JA, de Francisco AL, del Arco C et al. Serum levels of 1,25-dihydroxyvitamin D after renal transplantation. Miner Electrolyte Metab 1988; 14: 332-337
25. Bhan I, Shah A, Holmes J et al. Post-transplant hypophosphatemia: tertiary 'hyper-phosphatoninism'? Kidney Int 2006; 70: 1486-1494
26. Evenepoel P, Naesens M, Claes K et al. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007; 7: 1193-1200
27. +-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 2003; 278: 2206-2211
28. Tenenhouse HS, Sabbagh Y. Novel phosphate-regulating genes in the pathogenesis of renal phosphate wasting disorders. Pflugers Arch 2002; 444: 317-326
29. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26: 345-348
30. Movsowitz C, Epstein S, Fallon M et al. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988; 123: 2571-2577
31. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res 1996; 11: 1-7
32. McIntyre HD, Menzies B, Rigby R et al. Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens. Clin Transplant 1995; 9: 20-24
33. Grotz W, Mundinger A, Gugel B et al. Missing impact of cyclosporine on osteoporosis in renal transplant recipients. Transplant Proc 1994; 26: 2652-2653
34. Monegal A, Navasa M, Guanabens N et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 2001; 68: 83-86
35. Weinstein RS, Jilka RL, Parfitt AM et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102: 274-282
36. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104: 648-651
37. Hahn TJ, Halstead LR, Baran DT. Effects of short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab 1981; 52: 111-115
38. Reid IR, Ibbertson HK. Evidence for decreased tubular reabsorption of calcium in glucocorticoid-treated asthmatics. Horm Res 1987; 27: 200-204
39. Kaji H, Sugimoto T, Kanatani M et al. Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2. J Bone Miner Res 1997; 12: 734-741
40. Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis 2005; 45: 638-649
41. Wissing KM, Broeders N, Moreno-Reyes R et al. A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 2005; 79: 108-115
42. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996; 97: 2692-2696
43. Monier-Faugere MC, Mawad H, Qi Q et al. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 2000; 11: 1093-1099
44. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006; 7: 508-514
45. European best practice guidelines for renal transplantation (part 1). Nephrol Dial Transplant 2000; 15(Suppl 7): 1-85
46. Caravaca F, Fernandez MA, Ruiz-Calero R et al. Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients. Nephrol Dial Transplant 1998; 13: 2605-2611
47. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90: 1519-1524
48. Stevens LA, Djurdjev O, Cardew S et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779
49. Balal M, Paydas S, Seyrek N et al. Dipyridamole for renal phosphate leak in successfully renal transplanted hypophosphatemic patients. Clin Nephrol 2005; 63: 87-91
50. Julian BA, Quarles LD, Niemann KM. Musculoskeletal complications after renal transplantation: pathogenesis and treatment. Am J Kidney Dis 1992; 19: 99-120
51. Schwarz A, Rustien G, Merkel S et al. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant 2007; 22: 584-591
52. Hodsman AB, Kisiel M, Adachi JD et al. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone 2000; 27: 311-318
53. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausalwomenwith osteoporosis. N Engl J Med 2001; 344: 1434-1441
54. Akaberi S, Lindergard B, Simonsen O et al. Impact of parathyroid hormone on bone density in long-term renal transplant patients with good graft function. Transplantation 2006; 82: 749-752
55. Rostaing L, Moreau-Gaudry X, Baron E et al. Changes in blood pressure and renal function following subtotal parathyroidectomy in renal transplant patients presenting with persistent hypercalcemic hyperparathyroidism. Clin Nephrol 1997; 47: 248-255
56. Endlich K, Massfelder T, Helwig JJ et al. Vascular effects of parathyroid hormone and parathyroid hormone-related protein in the split hydronephrotic rat kidney. J Physiol 1995; 483(Pt 2): 481-490
57. Massfelder T, Parekh N, Endlich K et al. Effect of intrarenally infused parathyroid hormone-related protein on renal blood flow and glomerular filtration rate in the anaesthetized rat. Br J Pharmacol 1996; 118: 1995-2000
58. Jespersen B, Randlov A, Abrahamsen J et al. Effects of PTH(1-34) on blood pressure, renal function, and hormones in essential hypertension: the altered pattern of reactivity may counteract raised blood pressure. Am J Hypertens 1997; 10: 1356-1367
59. Lee PP, Schiffmann L, Offermann G et al. Effects of parathyroidectomy on renal allograft survival. Kidney Blood Press Res 2004; 27: 191-196
60. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl JMed 2004; 350: 1516-1525
61. Cunningham J, Danese M, Olson K et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800
62. Harris RZ, Padhi D, Marbury TC et al. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 2004; 44: 1070-1076
63. Goodman WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 1017-1024
64. El Agroudy AE, El Husseini AA, El Sayed M et al. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int 2005; 67: 2039-2045
65. Serra AL, Savoca R, Huber AR et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007; 22: 577-583
66. Thervet E, Legendre C, Beaune P et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005; 6: 37-47
67. Jean G, Chazot C, Charra B. Six cases of successful cinacalcet cessation in haemodialysis patients treated for secondary hyperparathyroidism. Nephrol Dial Transplant 2007; 22: 2102-2103
68. Stehman-Breen CO, Sherrard DJ, Alem AM et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 2200-2205
69. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. Nephrol Dial Transplant 2002; 17(Suppl 4): 20-21
70. Christiansen C, Rodbro P, Christensen MS et al. Is 1,25-dihydroxycholecalciferol harmful to renal function in patients with chronic renal failure? Clin Endocrinol (Oxf) 1981; 15: 229-236
71. Grotz W, Nagel C, Poeschel D et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001; 12: 1530-1537
72. Kovac D, Lindic J, Kandus A et al. Prevention of bone loss with alendronate in kidney transplant recipients. Transplantation 2000; 70: 1542-1543
73. Nowacka-Cieciura E, Cieciura T, Baczkowska T et al. Bisphosphonates are effective prophylactic of early bone loss after renal transplantation. Transplant Proc 2006; 38: 165-167
74. Kruse AE, Eisenberger U, Frey FJ et al. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1311-1314
75. Serra AL, Schwarz AA, Wick FH et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1315-1319
76. Szwarc I, Argiles A, Garrigue V et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006; 82: 675-680
77. Leca N, Laftavi M, Gundroo A et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant 2006; 6: 2391-2395
78. El Amm JM, Doshi MD, Singh A et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007; 83: 546-549